EFG Asset Management North America Corp. Raises Holdings in Eli Lilly and Company $LLY

Key Points

• EFG Asset Management North America Corp. has increased its holdings in Eli Lilly and Company by 249.6% in the first quarter, now owning approximately $9.71 million worth of the stock.
• Eli Lilly reported earnings of $6.31 per share, exceeding analysts' expectations, with a revenue of $15.56 billion for the quarter, up 37.6% year-over-year.
• The company announced a quarterly dividend of $1.50 per share, which translates to an annualized dividend yield of 0.8%.

EFG Asset Management North America Corp. lifted its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 249.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 11,761 shares of the company's stock after buying an additional 8,397 shares during the period. Eli Lilly and Company comprises approximately 1.6% of EFG Asset Management North America Corp.'s holdings, making the stock its 7th largest holding. EFG Asset Management North America Corp.'s holdings in Eli Lilly and Company were worth $9,710,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. WestEnd Advisors LLC boosted its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company during the 1st quarter worth $27,000. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock worth $35,000 after buying an additional 27 shares during the period. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter worth $40,000. Finally, Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the 4th quarter worth $43,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Down 2.2%

Shares of NYSE LLY traded down $16.56 during mid-day trading on Friday, hitting $726.35. The company had a trading volume of 3,953,474 shares, compared to its average volume of 5,282,453. The company has a market capitalization of $687.46 billion, a PE ratio of 47.47, a price-to-earnings-growth ratio of 1.03 and a beta of 0.47. The firm has a 50-day simple moving average of $743.84 and a two-hundred day simple moving average of $781.81. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a one year low of $623.78 and a one year high of $942.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter last year, the company posted $3.92 earnings per share. Eli Lilly and Company's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.8%. The ex-dividend date is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Insider Buying and Selling at Eli Lilly and Company

In related news, Director Jamere Jackson purchased 200 shares of the stock in a transaction dated Friday, August 8th. The stock was bought at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the acquisition, the director directly owned 2,703 shares of the company's stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several brokerages recently commented on LLY. Deutsche Bank Aktiengesellschaft dropped their price objective on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research note on Monday, August 11th. Wall Street Zen raised Eli Lilly and Company from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 30th. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Guggenheim dropped their price target on Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research note on Wednesday, August 13th. Finally, Hsbc Global Res raised Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of "Moderate Buy" and an average price target of $950.17.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.